Compare NICE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | LQDA |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | Israel | United States |
| Employees | 9626 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.5B |
| IPO Year | N/A | 2020 |
| Metric | NICE | LQDA |
|---|---|---|
| Price | $87.87 | $71.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $153.46 | $41.00 |
| AVG Volume (30 Days) | 710.4K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $10.14 | $278.87 |
| Revenue Next Year | $9.62 | $57.13 |
| P/E Ratio | ★ $11.21 | $125.48 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $84.38 | $11.85 |
| 52 Week High | $175.00 | $66.78 |
| Indicator | NICE | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 77.57 |
| Support Level | $86.40 | $31.23 |
| Resistance Level | $116.83 | N/A |
| Average True Range (ATR) | 3.94 | 4.10 |
| MACD | -0.15 | 0.26 |
| Stochastic Oscillator | 19.06 | 97.75 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.